Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2023-09-01 Penser Access Penser Access: IVACC Q2’23 - Intervacc Pressreleaser Visa Stäng
2023-08-31 Intervacc Intervacc: Delårsrapport januari - juni 2023 Rapporter Ladda ner | Visa Stäng
2023-08-31 Intervacc Intervacc: Interim report January - June 2023 Rapporter Ladda ner | Visa Stäng
2023-08-21 Intervacc Andreas Andersson steps down as President and CEO. Jonas Sohlman has been appointed acting President and CEO for Intervacc Pressreleaser Ladda ner | Visa Stäng
2023-08-21 Intervacc Andreas Andersson slutar som VD och koncernchef - Jonas Sohlman har utsetts som tillförordnad VD och koncernchef för Intervacc Pressreleaser Ladda ner | Visa Stäng
2023-08-17 Intervacc Intervacc awarded grant to optimise production processes for a fusion protein, which is one component of a prototype vaccine for pigs Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 17 Aug 2023 | Intervacc

Intervacc awarded grant to optimise production processes for a fusion protein, which is one component of a prototype vaccine for pigs

Intervacc’s innovative technology utilises fusion proteins in vaccines to generate broad-acting immune responses that provide protection to animals from complex bacterial diseases. Streptococcus suis causes meningitis, sepsis and arthritis in young piglets, leading to significant costs to the pig industry throughout the world. Early proof-of-concept studies found that the consumption of colostrum from sows that were vaccinated with Intervacc’s prototype vaccine against Streptococcus suis provided significant levels of protection to piglets at 4 and 7 weeks of age against challenge with a virulent strain of Streptococcus suis.

Testa Center provide access to a lab environment with a modern, pilot-scale testbed to optimise the scale-up processes required to manufacture biologics. The new industrial research project provides a grant to Intervacc of 800k SEK funded by Vinnova, which corresponds to about 70% of the cost of this development phase at Testa Center.

”We are very pleased to be extending our work with Testa Center to begin the development of the scale-up processes required to produce our prototype vaccine to protect piglets against Streptococcus suis infection,” said Dr. Andrew Waller, CSO of Intervacc, ”this new project represents another step on our path towards easing the burden caused by this important swine pathogen, in addition to minimising the requirement to treat this infection with antimicrobial agents.”

”At Testa Center we are delighted to be providing our expertise and facilities to help Intervacc optimise the small-scale manufacturing processes of this first vaccine component in preparation for further manufacturing and testing,” stated Dr. Jesper Hedberg, CEO of Testa Center.

For more information please contact:

Andreas Andersson, CEO

Phone: +46-8-120 10 601, cell +46-73-335 99 70
E-mail: andreas.andersson@intervacc.com

The information was submitted for publication, through the agency of the contact person set out above on August 17, 2023, 15.10 CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company’s vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Sciences where the foundation was laid for the Company’s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

About Testa Center

Testa Center is a private-public initiative between the Swedish government and Cytiva to secure the growth of the life science industry and its manufacturing capabilities. The main objective is to bridge the gap from discovery to industrialization. The Testa Center has the expertise and the equipment to help teams scale up from lab bench-scale to industrial-scale production. Testa Center is operated as a non-profit company. Visit testacenter.com ( http://www.testacenter.com ) for more information.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se,Phone: +46 (0)8 – 684 211 10

2023-08-17 Intervacc Intervacc beviljas bidrag för att utveckla tillverkningsprocessen för ett prototypvaccin för grisar Pressreleaser Ladda ner | Visa Stäng
2023-07-11 Intervacc Intervaccs beviljas medel för uppstartsfasen i ett utvecklingsprojekt som avser att ta fram tillverkningsprocesser för ett prototypvaccin mot Streptococcus suis infektioner hos gris Pressreleaser Ladda ner | Visa Stäng
2023-07-11 Intervacc Intervacc to collaborate with Testa Center to optimise production processes for their prototype vaccine for pigs Pressreleaser Ladda ner | Visa Stäng
2023-07-10 Intervacc Intervacc ställer ut på Falsterbo Horse Show Pressreleaser Ladda ner | Visa Stäng
2023-06-08 Intervacc Intervacc announces the outcome of the fully secured rights issue Pressreleaser Ladda ner | Visa Stäng
2023-06-08 Intervacc Intervacc offentliggör utfall i den fullt säkerställda företrädesemissionen Pressreleaser Ladda ner | Visa Stäng
2023-06-07 Intervacc Report from Annual General Meeting in Intervacc Pressreleaser Ladda ner | Visa Stäng
2023-06-07 Intervacc Kommuniké från årsstämman i Intervacc AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-05-22 Intervacc Intervacc AB (publ) publishes prospectus in connection with a fully covered rights issue Pressreleaser Ladda ner | Visa Stäng
2023-05-22 Intervacc Intervacc AB (publ) offentliggör prospekt i samband med fullt säkerställd företrädesemission Pressreleaser Ladda ner | Visa Stäng
2023-05-17 Intervacc Intervacc: The European Medicines Agency (EMA) approves extention of shelf life for Strangvac, a vaccine against equine strangles, to 33 months Pressreleaser Ladda ner | Visa Stäng
2023-05-17 Intervacc Intervacc: Europeiska läkemedelsmyndigheten (EMA) godkänner förlängning av hållbarheten för Strangvac, ett vaccin mot kvarka, till 33 månader Pressreleaser Ladda ner | Visa Stäng
2023-05-15 Penser Access Penser Access: Villkoren för företrädesemissionen kommunicerade - Intervacc Pressreleaser Visa Stäng
2023-05-11 Intervacc Styrelsen i Intervacc har beslutat om en fullt säkerställd företrädesemission om cirka 104 miljoner kronor Pressreleaser Ladda ner | Visa Stäng
2023-05-11 Intervacc The Board of Directors in Intervacc has resolved on a fully covered rights issue of approximately SEK 104 million Pressreleaser Ladda ner | Visa Stäng
2023-05-08 Intervacc Intervacc: Veterinary Medicines Directorate (VMD) extends the shelf life for Strangvac, a vaccine against equine strangles, to 33 months Pressreleaser Ladda ner | Visa Stäng
2023-05-08 Intervacc Intervacc: Veterinary Medicines Directorate (VMD) förlänger hållbarheten för Strangvac, ett vaccin mot kvarka, till 33 månader i Storbritannien Pressreleaser Ladda ner | Visa Stäng
2023-05-05 Intervacc Intervacc: CORRECTION: NOTICE OF ANNUAL GENERAL MEETING IN INTERVACC AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-05-05 Intervacc Intervacc: RÄTTELSE: KALLELSE TILL ÅRSSTÄMMA I INTERVACC AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-05-05 Intervacc Intervacc: KALLELSE TILL ÅRSSTÄMMA I INTERVACC AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-05-05 Intervacc Intervacc: NOTICE OF ANNUAL GENERAL MEETING IN INTERVACC AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-05-05 Intervacc Report from Extraordinary General Meeting in Intervacc Pressreleaser Ladda ner | Visa Stäng
2023-05-05 Intervacc Kommuniké från extra bolagsstämma i Intervacc AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-05-04 Penser Access Penser Access: Försäljningsstarten tar längre tid än väntat - Intervacc Pressreleaser Visa Stäng
2023-05-03 Intervacc Intervacc: Delårsrapport januari - mars 2023 Rapporter Ladda ner | Visa Stäng
2023-05-03 Intervacc Intervacc: Interim report January - March 2023 Rapporter Ladda ner | Visa Stäng
2023-04-19 Intervacc Intervacc: KALLELSE TILL EXTRA BOLAGSSTÄMMA I INTERVACC AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-04-19 Intervacc Intervacc: NOTICE OF EXTRAORDINARY GENERAL MEETING IN INTERVACC AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-04-19 Intervacc Styrelsen i Intervacc avser att besluta om en fullt säkerställd företrädesemission om cirka 100 miljoner kronor Pressreleaser Ladda ner | Visa Stäng
2023-04-19 Intervacc The Board of Directors in Intervacc intends to resolve on a fully covered rights issue of approximately SEK 100 million Pressreleaser Ladda ner | Visa Stäng
2023-04-06 Intervacc Intervacc publishes the 2022 Annual Report Pressreleaser Ladda ner | Visa Stäng
2023-04-06 Intervacc Intervacc publicerar årsredovisning för 2022 Pressreleaser Ladda ner | Visa Stäng
2023-02-22 Intervacc Förtydligande angående insynsförsäljning i Intervacc AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-02-21 Penser Access Penser Access: Intervju med Intervacc - Erik Penser Bank - 21 februari 2023 Pressreleaser Visa Stäng
2023-02-20 Penser Access Penser Access: Långsiktiga finansiella mål kommunicerade - Intervacc Pressreleaser Visa Stäng
2023-02-17 Intervacc Intervacc: Year-end report January - December 2022 Pressreleaser Ladda ner | Visa Stäng
2023-02-17 Intervacc Intervacc: Bokslutskommuniké januari - december 2022 Pressreleaser Ladda ner | Visa Stäng
2023-01-24 Intervacc Intervaccs forskningschef Dr Andrew Waller presenterar på FEEVA European Horse Welfare Symposium i Amsterdam Pressreleaser Ladda ner | Visa Stäng
2023-01-24 Intervacc Intervacc's Chief Scientific Officer Dr Andrew Waller presents at the FEEVA European Horse Welfare Symposium in Amsterdam Pressreleaser Ladda ner | Visa Stäng
2023-01-23 Intervacc Intervaccs forskningschef Dr Andrew Waller presenterar på Veterinary Sport Horse Congress i Amsterdam Pressreleaser Ladda ner | Visa Stäng
2023-01-23 Intervacc Intervacc's Chief Scientific Officer Dr Andrew Waller presents at the Veterinary Sport Horse Congress in Amsterdam Pressreleaser Ladda ner | Visa Stäng
2022-12-19 Intervacc Intervacc och Sveriges lantbruksuniversitet, SLU, förnyar flerårigt samarbetsavtal för vidareutveckling av vacciner inom djurhälsa Pressreleaser Ladda ner | Visa Stäng
2022-12-19 Intervacc Intervacc and the Swedish University of Agricultural Sciences, SLU, extends a multi-year contract for the development of innovative animal health vaccines Pressreleaser Ladda ner | Visa Stäng
2022-12-13 Intervacc Intervacc: Strangvac, ett vaccin mot kvarka, frisläppt för försäljning i Italien Pressreleaser Ladda ner | Visa Stäng
2022-12-13 Intervacc Intervacc: Strangvac, a vaccine against equine strangles released for sales in Italy Pressreleaser Ladda ner | Visa Stäng
2022-11-28 Intervacc Intervacc: Försäljningsstart i Polen för Strangvac, ett vaccin mot kvarka Pressreleaser Ladda ner | Visa Stäng
2022-11-28 Intervacc Intervacc: Strangvac, a vaccine against equine strangles, is now available for sale in Poland Pressreleaser Ladda ner | Visa Stäng
2022-11-24 Intervacc Intervacc's Chief Scientific Officer Dr Andrew Waller participate at the Dutch Equine Conference Pressreleaser Ladda ner | Visa Stäng
2022-11-24 Intervacc Intervaccs Chief Scientific Officer Dr Andrew Waller medverkar på Dutch Equine Conference Pressreleaser Ladda ner | Visa Stäng
2022-11-16 Intervacc Intervacc's Chief Scientific Officer Dr Andrew Waller will speak about the prevention of equine strangles at the London Vet Show Pressreleaser Ladda ner | Visa Stäng
2022-11-16 Intervacc Intervaccs Chief Scientific Officer Dr Andrew Waller föreläser om kvarka på London Vet Show Pressreleaser Ladda ner | Visa Stäng
2022-11-15 Intervacc Intervacc: Strangvac sales to start in Ireland Pressreleaser Ladda ner | Visa Stäng
2022-11-15 Intervacc Intervacc: Försäljningsstart för Strangvac i Irland Pressreleaser Ladda ner | Visa Stäng
2022-11-11 Intervacc Nomination Committee appointed in respect of AGM 2023 in Intervacc Pressreleaser Ladda ner | Visa Stäng
2022-11-11 Intervacc Valberedning utsedd inför årsstämma 2023 i Intervacc Pressreleaser Ladda ner | Visa Stäng
2022-11-11 Penser Access Penser Access: Strangvac till försäljning på de viktigaste europeiska marknaderna - Intervacc Analyser Visa Stäng
2022-11-10 Intervacc Intervacc: Delårsrapport januari - september 2022 Rapporter Ladda ner | Visa Stäng
2022-11-10 Intervacc Intervacc: Interim report January - September 2022 Rapporter Ladda ner | Visa Stäng
2022-10-12 Intervacc Intervacc: Strangvac, ett vaccin mot kvarka, frisläppt för försäljning i Tyskland, Frankrike, Österrike och Benelux Pressreleaser Ladda ner | Visa Stäng
2022-10-12 Intervacc Intervacc: Strangvac, a vaccine against equine strangles released for sales in Germany, France, Austria and the Benelux Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

16 Nov 2023 | Kvartalsrapport 2023-Q3
16 Feb 2024 | Bokslutskommuniké 2023